Abstract Library

#2291 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells

Introduction: Neuroendocrine tumors (NETs) express somatostatin receptors that are currently utilized for diagnostic and therapeutic approaches. For peptide receptor radionuclide therapy (PRRT), somatostatin analogs are coupled to radionuclides like 90Y or 177Lu, which after injection are bound and taken up specifically by NETs. One hypothesis potentially explaining the discrepancies between expected result and observed outcome of PRRT might be that somatostatin analogs induce a G1 arrest in NET cells, thereby rendering them radioresistant.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Grötzinger C

Authors: Grötzinger C, Exner S, Prasad V, Erdmann S, Wiedenmann B,

Keywords: PRRT,

#2001 The Anticancer Mechanism of Metformin in Pancreatic Neuroendocrine Tumor Cells

Introduction: Metformin, a widely used antidiabetic drug, has been reported to display potent anticancer properties in various types of cancers. In P-NETs, aryl hydrocarbon receptor-interacting protein (AIP) acts as a tumor suppressor and is up-regulated by the somatostatin analog octreotide.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Lania A

Authors: Vitali E, Piccini S, Boemi I, Brambilla T, Zerbi A,

Keywords: GEP-NET, Metformin, AIP,

#1506 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells

Introduction: PRRT can deliver radiation doses of up to 250 Gy to the tumors. Nevertheless, complete remission is extremely rare, compared to similar radiotherapies for thyroid cancer and non-Hodgkin lymphoma.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Exner S, Erdmann S, Wiedenmann B, Prasad V, Grötzinger C,

Keywords: PRRT,

#1075 Filamin-A Is Required for Somatostatin Receptor 2 (SST2) Stabilization, Signaling and Angiogenesis Regulation in Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Somatostatin receptor type 2 (SST2) is the main pharmacological target for GEP-NETs. A subset of patients is resistant to somatostatin analogs (SSa), although the molecular mechanisms responsible for resistance are poorly understood. Several studies identified cytoskeleton protein as determinant in receptor anchoring and signaling

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Vitali E, Cambiaghi V, Loiarro F, Zerbi A, Colombo P,

Keywords: FLNA, SST2, GEP-NET,

#894 The Effects of cAMP in Different Neuroendocrine Tumorous Cells: The Role of Epac and PKA in Cell Proliferation and Cell Adhesion

Introduction: cAMP is implicated in the inhibition or stimulation of proliferation depending on cell type. Although the effects exerted by cAMP were initially attributed to the PKA activation, two cAMP-activated guanine nucleotide exchange (Epac1/2) have been later identified as cAMP targets.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Vitali E, Zerbi A, Peverelli E, Mantovani G, Cambiaghi V,

Keywords: cAMP, PKA, EPAC, GEP-NET,